Loss of exomiR-128b, an EGFR regulator, was associated with better response to gefitinib, an EGFR inhibitor, in patients with relapsed NSCLC (Weiss et al., 2008) and high expression levels of exomiR-21 were found in patients with vertebral column metastasis through increased expression of COX-19 (Guo et al., 2015). Here, EGFR is linked to non-small cell lung carcinoma.